Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain Abstract #1389
Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Aim(s): The experience of 12 centers in Spain with this scheme is presented.
Materials and methods: We retrospectively reviewed patients with NETs G1-2 of any origin treated with capecitabine (750-1000 mg/m2 twice daily days 1-14) and temozolomide (150-200 mg/m2 days 10-14) every 28 days, from June 2009 to August 2015.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
Authors:
Crespo G H, Jimenez-Fonseca P, Custodio A, Lopez C, Carmona-Bayonas A, Alonso V, Navarro M, Aller J, Sevilla I, Gajate P, Alonso T, Matos I, Capdevila J, Nieto B, Barriuso J
Keywords:
capecitabine, temozolomide
To read results and conclusion, please login ...
Further abstracts you may be interested in
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
#709 Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs
Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: María Jesús Barrio
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
#950 Outcome of Malignant Insulinomas (MI) in the Community Setting
Introduction: MI is a rare and difficult to handle functional pancreatic neuroendocrine tumor with a variety of therapeutic alternatives.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: MD Carlos Lopez Lopez
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio